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Abstract: Alterations in chromatin structure profoundly influence gene expression during normal cellular homeostasis 
and malignant transformation. Methylation of cytosines within CpG islands located in promoter and proximal coding re-
gions facilitates recruitment of chromatin-remodeling proteins, which inhibits gene expression. Posttranslational modifica-
tions, such as acetylation, methylation, and phosphorylation, of core histone proteins ‘‘mark’’ regions of chromatin for 
recognition by multiprotein complexes, which promote either chromatin relaxation and gene expression or chromatin 
compaction and repression of gene expression. Many genes become transcriptionally silenced during the development of 
cancer. Covalent epigenetic modifications such as DNA hypermethylation and histone post-translational modifications are 
an important early event during carcinogenesis and tumor development. Genes involved in key DNA damage responses 
pathways, apoptosis signaling and DNA repair, can frequently become methylated and epigenetically silenced in tumors. 
This may lead to differences in intrinsic sensitivity of tumors to chemotherapy, depending on the specific function of the 
gene inactivated. The fact that cancer can have an epigenetic etiology has encouraged the development of a new therapeu-
tic option that might be termed “epigenetic therapy”. The DNA methylation paradox, manifested as derepression of can-
cer-testis antigens and silencing of tumor suppressors during malignant transformation, provides rationale for the utiliza-
tion of chromatin remodeling agents for cancer therapy. In this review, the recent advances in the understanding and clini-
cal development of DNA methyltransferase and Histone deacetylase inhibitors, as well as their current role in cancer ther-
apy, will be discussed. 
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INTRODUCTION 
DNA methylation is a major epigenetic modification of 
the genome that regulates crucial aspects of its function. 
Epigenetic modifications, which include covalent modifica-
tion of bases in the DNA and of amino-acid residues in the 
histones, are generally stable and heritable in somatic differ-
entiated cells. The methylation profile of the cell is exqui-
sitely controlled during development. In germ cells and in 
pre-implantation embryos there are at least two developmen-
tal periods in which methylation patterns are reprogrammed 
genome wide, generating cells with a broad developmental 
potential. Epigenetic reprogramming is critical and affects 
the imprinting in germ cells and early embryos [1]. Repro-
gramming is likely to have a crucial role in establishing nu-
clear totipotency in normal development, in stem cell differ-
entiation and in ensuring acquired epigenetic information. 
The existence of an epigenetic-based cellular memory, or 
program, serves to regulate global patterns of gene expres-
sion and is the basis of genome defence mechanisms that 
silences viruses and trasposons [2]. The engines of epige-
netic change in mammals are the DNA methylation, a 
chemical modification to DNA, and changes in chromatin 
structure resulting from histone modifications. These DNA 
chromatin modifications are potentially reversible and modu-
late gene expression without changing DNA sequence and 
without any new genetic information. Chromatin remodeling  
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by nucleosome reorganization at the site of the promoter 
genes enables transcriptional regulation. Histone acetylation 
and DNA methylation are the two best characterized epige-
netic modifications to which histone methylation, phos-
phorylation and ubiquitination must be added. Histone 
acethyla tion and DNA methylation are interdependent and 
their equilibrium contributes to regulate gene expression [3]. 
CpG methylation appears to differ from histone modifica-
tions because it bestows a persistent epigenetic memory in-
dependently of histone modifications, which appears to be 
limited in this capacity. Within the DNA methylation 
changes there are regional specific differences in the methy-
lation pattern. The genome appears to be compartmentalized 
with respect to methylation of CpG sites. The methylated 
compartments appear to coincide with the regions of gene 
inactivity whereas the unmethylated compartments coincide 
with regions of gene activity. Repeated sequences which 
comprise up to 35% of the genome are generally hyper-
methylated while the CpG sites within the promoter region 
and first exon of house-keeping genes and of tissue-specific 
genes are unmethylated [4].  
In contrast to normal cells, the methylation pattern in 
cancer cells is disrupted with the major changes in the meth-
ylation compartments of the cells. The normally hyper-
methylated and silenced regions containing repetitive ele-
ments and oncogenes are demethylated while unmethylated 
CpG island containing tumor suppressor genes often become 
hypermethylated and inactivated [5, 6]. In cancerous cells, 
the total content of methyl cytosine is reduced by about 40% 
and it has been proposed that this hypomethylation contrib-
ute to malignancy by either contributing directly to the acti-
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vation of oncogenes, activation of latent retrotrasposons and 
/or chromosome instability [7]. However, there is also a 
marked increase in the methylation of specific genomic re-
gions, called CpG islands. These regions are located within 
the vicinity of promoters for genes that carry out basic func-
tions of cells. Based on research efforts to understanding the 
impact of epigenetic on cancer, it has been established that 
an excessive methylation of tumor suppressor genes is a 
common hallmark of all human cancer. Genes involved in 
cell cycle regulation, DNA repair, drug resistance, detoxifi-
cation, differentiation, apoptosis, angiogenesis and metasta-
sis have all been identified as being susceptible to hyper-
methylation in different cancer cells [8]. The fact that can-
cers have an epigenetic etiology has encouraged the devel-
opment of a new therapeutic option that might be termed 
“epigenetic therapy”. The DNA methylation paradox, mani-
fested mostly as silencing of tumor suppressors during ma-
lignant transformation, provides the rationale for the utiliza-
tion of chromatin remodeling agents for cancer therapy. 
INSIGHTS ON MOLECULAR MACHINERY FOR 
EPIGENETIC GENE SILENCING 
The best studied epigenetic modifications are DNA 
methylation and post-translational histone modifications. 
DNA methylation is the covalent addition of a methyl group 
to the DNA, predominantly to the base cytosine 5’ to gua-
nine, also called CpG dinucleotide. DNA methylation is 
catalysed by DNA methyltransferases (DNMTs), of which 
three active enzymes have been identified in mammals, 
namely DNMT1, DNMT3a and DNMT3b. The DNMT1 is 
responsible for maintaining the pre-existing methylation pat-
terns following DNA replication, while DNMT3a and 
DNMT3b are required for initiation of de novo methylation 
[9, 10]. Several evidences indicate that the three DMNTs not 
only cooperate but also may process both de novo and main-
tenance functions in vivo [11, 12]. The methylated DNA is in 
part interpreted by methyl-binding domain proteins (MBDs), 
including MeCP2 and MBD 1-4. These MBD proteins are 
important “translators” between DNA methylation and his-
tone-modifier genes that establish a transcriptionally inactive 
chromatin environment. Most of hypermetylated promoters 
are occupied by a particular set of MBD proteins, which 
seem to be gene and tumor-type-specific. The treatment of 
cancer cells with demethylating agents causes CpG island 
demethylation, MBD release and gene re-expression, rein-
forcing the notion that association of MBDs with methylated 
promoters is methylation-dependent. The finding that 
MeCP2 repress transcription of methylated DNA through the 
recruitment of histone deacetylase-containing complex, es-
tablishes a mechanistic connection between DNA methyla-
tion and transcriptional repression by the modification of 
chromatin. Chromatin remodeling by nucleosome re-
organization at the site of promoter genes enables transcrip-
tional regulation [13]. At the nucleosome level the DNA 
helix is wrapped around the histone proteins, which are sub-
jected to various modifications as acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, ADP-
ribosylation, glycosylation, biotinylation and carbonylation. 
The totality of histone modifications, or “histone code”, is 
read by proteins involved in chromatin remodeling, tran-
scriptional activation or repression, and thereby govern 
chromatin dynamics and gene transcription. In particular, 
histone acetylation, which is controlled by histone acetyl-
transferases (HATs), generally correlates to an open and 
transcriptionally active chromatin state, whereas histone 
deacetylation, controlled by histone deacetylases (HDACs), 
is associated with chromatin condensation and transcrip-
tional repression. Thus, hypermethylated CpG islands of 
silenced tumor suppressor genes are known to display a his-
tone code or post-translational modifications characterized 
by histone hypoacetylation and histone methylation [14]. A 
close interconnection between DNA and histone modifica-
tions has been found in gene silencing. DNMTs are able to 
recruit HDACs, and both DNMTs and MBDs recruit histone 
methyltransferases (HMTs) that modify lysine 9 of histone 
H3 [15]. In the hypermethylated promoters this active re-
cruitment of multiple repressors leads to a characteristic his-
tone modification pattern featuring deacetylation of histone 
H3 and H4, methylation of lysine 9 of histone H3, and de-
methylation of lysine 4 of histone H3 [16]. Another connec-
tion between various repression systems is highlighted by 
Polycomb proteins. These proteins are involved in silencing 
“master genes” involved in major developmental processes 
and are found to cooperate with DNMTs and MBD proteins 
to establish DNA methylation in a subset of target genes [17, 
18].  
Thus, among the multitude of proteins which crowd the 
promoter of epigenetically silenced genes, it is clear that 
some proteins, such as MBDs, are more permanent residents 
and other, such as DNMTs, HDACs, HMTs and Polycomb, 
intermix to maintain a chromatin conformation compatible 
with stable epigenetic transcriptional silencing. 
ROLE OF DNA HYPERMETHYLATION AND HIS-
TONE DEACETYLATION IN THE PATHOGENESIS 
OF CANCER 
1. Aberrant DNA Methylation and Cancer Development 
Cancer is a stepwise process of accumulation of genetic 
and epigenetic abnormalities that can lead to cellular dys-
function and the synergy of these two processes drives tumor 
progression and malignancy. The most emphasized alteration 
of DNA methylation in cancer is the aberrant hypermethyla-
tion of CpG islands surrounding promoter regions [19]. A 
growing number of tumor-suppressor and other cancer-
related genes have been demonstrated to be silenced by aber-
rant promoter methylation. De novo methylation of 'CpG 
islands' in the promoter regions of tumor suppressor genes 
may lead to transcriptional silencing through a complex 
process involving histone deacetylation and chromatin con-
densation, and thus represents a tumorigenic event that is 
functionally equivalent to genetic changes, like mutation and 
deletion [20]. The genes affected include over half of the 
tumor suppressor genes that cause familial cancers when 
mutated in the germ line. The selective advantage for genetic 
and epigenetic dysfunction in these genes is very similar. For 
some genes, the promoter methylation may be the only type 
of gene inactivation found in human cancer, since mutations 
for many of genes are rare or have not been observed. The 
aberrant methylation can begin very early in tumor progres-
sion and mediate most of the important pathway abnormali-
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ties in cancer including loss of cell cycle control, altered 
function of transcription factors, altered receptor function, 
disruption of normal cell-cell and cell-substratum interac-
tions, inactivation of signal transduction pathways, loss of 
pro-apoptotic signals and genetic instability. The profile of 
gene promoter hypermethylation differs for each cancer type, 
providing a tumor-type and gene-specific profile. This is 
consistent with a model in which methylation of CpG islands 
at particular genes would give to the cancer cell a growth or 
survival advantage and so aberrant patterns of methylation 
emerge depending on the selective pressure for gene silenc-
ing in the tumors type examined [21]. Some genes, such as 
the cell cycle inhibitor p16
INK4a
, are hypermethylated across 
many tumor types including colorectal, lung, and breast car-
cinomas. This alteration reflects the widespread contribution 
of disruptions of the cyclinD-Rb cell cycle control pathway 
in human cancer [22]. Other changes, such as for the DNA 
repair gene MGMT and DAPK, also have a wide distribution 
[23]. Hypermethylation of p14
ARF
 and APC are most preva-
lent in gastrointestinal tumors (i.e., colon and stomach) [24], 
whereas GSTP1 is characteristic of steroid-related neoplasm 
such as breast, liver, and prostate [25, 26]. The aberrant 
methylation of certain genes reflects their very specific in-
volvement in selected tumor types or groups of tumors. 
Methylation of Rb2/p130 is frequent in sporadic retinoblas-
toma but not in the familiar one [27]. BRCA1 was found 
hypermethylated only in breast and ovarian carcinomas [26], 
whereas hypermethylation of the mismatch repair gene 
hMLH1 is restricted to the three sporadic tumor types char-
acteristic of the hereditary nonpolyposis colorectal cancer 
syndrome: colorectal, endometrial, and gastric tumors with 
microsatellite instability [28]. Moreover, in any given tumor 
is possible to find simultaneous inactivation of several path-
ways by aberrant methylation compromising either cell sur-
vival or tumor progression genes. For example, the tumor 
may have disruption of cell cycle, DNA repair, and metasta-
sis-related process by hypermethylation of p16
INK4a
, hMLH1, 
and TIMP-3, respectively, whereas mammary tumor can 
accomplish similar objectives by silencing p16
INK4a
,BRCA1 
and CDH1 and a lung tumor affecting p16
INK4a
, MGMT and 
DAPK [29]. Deregulation of matrix degrading metalloprotei-
nase enzymes (MMPs) leads to increased extracellular ma-
trix turnover, a key event in the local invasion and metastasis 
of many tumors. Expression of tissue inhibitor of metallo-
proteinase-3 (TIMP-3), a secreted protein bound to the ex-
tracellular matrix, antagonizes
 
matrix metalloproteinase ac-
tivity and has been shown to inhibit many aspects of tumor 
development and metastatic progression, including growth, 
angiogenesis and invasion [30]. Decreased TIMP-3 expres-
sion has been observed in a variety of tumor cell lines and 
has been associated with CpG island methylation. Aberrant 
methylation of TIMP-3 occurs in primary cancers of the kid-
ney, brain, colon, breast and lung, but not in normal tissue 
and is particularly frequent, in renal cancer in which 78% of 
case has aberrant TIMP-3 methylation, with associated lack 
of protein expression [31]. Tumor-specific methylation of 
TIMP-3 may be a critical step during malignant progression. 
It is believable that loss of TIMP-3 may abrogate normal 
apoptotic programs, enhance primary tumor growth and an-
giogenesis, invasiveness and metastasis and possibly, there-
fore, contribute to all stages of malignant progression [32].  
In addition to silencing as a result of mutations, loss of 
heterozygosity, or classical genetic events, the epigenetic 
modification symbolizes essential early events during car-
cinogenesis and tumor development. The reversion of these 
epigenetic processes restoring normal expression of tumor-
suppressor genes has consequently become a new therapeutic 
target in cancer treatment. Aberrant patterns of epigenetic 
modifications will be, in a near future, crucial parameters in 
cancer diagnosis and prognosis. 
2. Aberrant DNA Methylation and Drug Resistance of 
Tumors 
One phenomenon common to both intrinsic and acquired 
resistance is aberrant alteration of gene expression in the 
drug-resistant tumor, which exceed in number respect to 
sensitive one. Although misregulation of gene expression has 
many origins, one such origin is via aberrant epigenetic regu-
lation. As well as affecting disease progression, gene silenc-
ing has potential to influence resistance and clinical outcome 
following therapy. A number of recent studies suggest a di-
rect role for epigenetic inactivation of genes in determining 
tumor chemosensitivity [33-35]. Aberrant deregulation of 
cell growth has traditionally been viewed as the major under-
lying mechanism for tumor formation; however, it is becom-
ing increasingly clear that cellular changes that lead to inhi-
bition of apoptosis play an essential role in tumor develop-
ment and cellular drug response [36]. Many cancer che-
motherapeutic drugs activate apoptotic mechanisms of tumor 
cell death, suggesting that factors that impair programmed 
cell death contribute to the resistance of tumor cells to cyto-
toxic drug treatment. Because the death of tumor cells in-
duced by chemotherapy and radiotherapy is largely mediated 
by activation of apoptosis, inhibition of apoptosis will make 
tumor cells resistant to anti-tumor treatment. Numerous 
works were devoted to the identification of the cell death 
pathways that were triggered in tumor cells following drug 
or radiation therapy [37]. The role of p53 as a mediator of 
cytotoxicity of chemotherapeutic drugs is well accepted and 
the loss of p53 function is a common feature in human tu-
mors contributing both to aggressive tumor behavior and to 
therapeutic resistance. p53 plays a pivotal role in modulating 
the cell responses to various sources of damage and stress by 
controlling the transcription of a large number of genes re-
quired for the apoptotic response [38]. Given that p53 plays a 
crucial and multivariate role in controlling cell growth and 
survival, it is not surprising that it has been found inactivated 
in the majority of cancers. Numerous genetic and epigenetic 
changes in the cancer cell may contribute to inactivate the 
function of oncosupressor genes thus leading to select a drug 
resistance phenotype. However, with the recognition of im-
portant roles for both p53 and its recently described paralog 
p73 in mediating the activity of anti-cancer drugs, there has 
been increasing recognition that cellular resistance to such 
agents can arise from failure of p53 family member signaling 
[39]. Whereas mutations of p53 occur commonly in tumors, 
inactivating mutations in the coding sequence of p73 are 
uncommon in human cancer. There are examples, particu-
larly in hematological neoplasm, in which methylation-
dependent silencing of p73 appears to occur in clinically 
aggressive cases and to correlate with poor response to thera-
py [40]. Another example is the osteosarcoma, which bears 
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mutations of both p53 and pRb1/p105 tumor suppressor 
genes, nevertheless these cells could still undergo apoptosis 
upon drug treatment in a p73-dependent pathways [41]. 
However, in total 30-40% of human osteosarcoma showed 
resistance after a few courses of chemotherapeutic treatment, 
which determinate the failure of therapy. It has been recently 
reported that multi-drug resistant (MDR) osteosarcoma fail-
ure the apoptotic response induced by chemotherapeutic 
drugs by maintaining repressed p73 transcription in a methy-
lation-dependent manner, suggesting that epigenetic events 
occur to select a MDR osteosarcoma variants [39]. Apaf-1 
represents another gene whose methylation may leads to 
increased resistance to chemotherapy. Metastatic melanoma 
is a very aggressive cancer that fails to respond to conven-
tional chemotherapy which often lacks Apaf-1, a cell-death 
effector that acts with cytochrome c and caspase-9 in induc-
ing p53-dependent apoptosis. Loss of Apaf-1 expression can 
be recovered in melanoma cell lines by treatment with the 
methylation inhibitor 5-aza-2-deoxycytidine thus suggesting 
that in these tumor histotype Apaf-1 is methylated. Apaf-1-
negative melanomas are invariably chemoresistant and are 
unable to execute a typical apoptotic program in response to 
p53 activation. Restoring physiological levels of Apaf-1 
through 5-aza-CdR treatment markedly enhances chemosen-
sitivity and rescues the apoptotic defects associated with 
Apaf-1 loss [42]. Methylation of other members of Apaf-1 
apoptotic network and caspase cascade can influence apopto-
sis and hence chemosensitivity. For example, the gene en-
coding for caspase-8 is frequently methylated in tumors and 
again demethylating agents can induce gene re-expression, 
increased apoptosis and chemosensitization [43]. The 
hMLH1 (mutL homologue 1) protein, part of the human 
DNA MMR (mismatch repair) system, has been shown to be 
important in determining sensitivity to a number of impor-
tant chemotherapeutic agents [44]. The majority of sporadic 
colon [45], gastric [46] and endometrial [47] cancers are 
hMLH1 deficient and exhibit promoter hypermethylation of 
this gene. Experimental evidence suggests that for some cy-
totoxic drugs, DNA MMR proteins provide a link between 
recognition of DNA damage and downstream effectors of an 
apoptotic response, such as p53 and p73 [48]. Loss of DNA 
MMR proficiency results in resistance in vitro to a number 
of clinically important anticancer drugs, including cisplatin 
and doxorubicin [49], and it has been associated with selec-
tion for drug-resistant breast and ovarian tumors during 
chemotherapy [50]. Reintroduction of the hMLH1 gene into 
the hMLH1 null mouse cells leads to sensitization to DNA 
damaging agents [51], supporting a direct involvement of 
DNA MMR in drug sensitivity and providing evidence that 
re-expression of hMLH1 can partially overcome MMR-
related drug resistance. In ovarian cancer, a higher frequency 
of hMLH1 promoter methylation
 
is observed in post chemo-
therapy tumors, suggesting that aberrant hMLH1 promoter 
hypermethylation occurs in selecting clones that acquired 
drug resistance after chemotherapy treatments. Re-
expression
 
of hMLH1 by treatment with the demethylating
 
agent 5-Aza-CdR results in sensitization of resistant variants
 
to cisplatin in vitro [52]. The observation that
 
demethylation 
of the hMLH1 gene promoter results in drug sensitization
 
in 
vitro raised the exciting possibility that MMR-related drug
 
resistance could be overcome clinically by demethylating 
agents. Several genes in ovarian cancer, including tumor 
suppressors and genes involved in apoptotic pathways re-
lated to chemotherapeutic action are down regulated by epi-
genetic mechanisms. Another tumor suppressor found to be 
methylated and silenced in ovarian cancer is the gene encod-
ing RASSF1A protein [53]. RASSF1A has been reported to 
bind to tubulin and stabilize microtubules [54] and it is pos-
sible hypothesize that this protein might ‘‘assist’’ che-
motherapeutics such as paclitaxel in mediating prevention of 
spindle assembly. Re-expression of RASSF1A by epigenetic 
drugs could, conceivably, resensitize resistant tumors to such 
taxanes. In ovarian cancer, drug resistance induced by epige-
netic events likely contributes to chemoresistance at several 
possible positions in drug response pathways. Epigenetic 
down regulation of Apaf-1, hMLH1, RASSF1A, p16
INK4a
 
and (possibly) p73 likely contributes to resistance, as well as 
the up regulation of FancF and MDR-1 in ovarian cancer 
[33]. 
While methylation of pro-apoptotic genes could lead to 
drug resistance, methylation of DNA repair genes, drug me-
tabolisms and detoxification genes (GSTp1, MDR1) during 
tumor development might lead to drug sensitivity. The multi-
drug resistance phenotype (MDR) is associated whit expres-
sion of the MDR1 gene that encodes the drug transporter P-
glycoprotein. P-gp protein is a member of the protein family, 
named ATP-binding cassette transporter proteins (ABC). 
These transmembrane proteins enhance drugs efflux in an 
energy dependent manner. The human ABC gene family 
consists of 48 members [55], and they are present in virtually 
every cell and play central role in physiology, working as 
efflux pumps in tissue defence [56]. Collectively, these pro-
teins are capable of transporting a vast and chemically di-
verse array of toxicants. The overexpression of ABC trans-
porters such as P-glycoprotein, the multi-drug resistance 
associated protein 1 (MRP1), MRP2 and the breast cancer 
resistance protein (BCRP) is associated with increased efflux 
of chemotherapeutic drugs such as anthracyclines, epipodo-
phyllotoxins and vinca-alkaloids, and this can result in the so 
called multi-drug resistance (MDR). The overexpression of 
P-gp has been associated with resistance to a wide range of 
anticancer drugs. P-glycoprotein confers cross-resistance to 
unrelated drugs that differ widely with respect to molecular 
structure and target specificity, including many natural prod-
uct agents (e.g., paclitaxel, vincristine, and doxorubicin) as 
well as new targeted anticancer agents (e.g., Gleevec) [57]. 
The precise mechanism of transcriptional regulation has 
been unclear due to the complex regulatory nature of the P-
gp gene. It has become increasingly apparent that trans-
activation or genetic amplification is by no means the only 
mechanism of activation. Consequently, alternative pathways 
have received more attention in the area of epigenetic events 
to help in explaining transcriptional competence at a higher 
level of organization. It has been shown an inverse correla-
tion between functional gene expression and MDR1 pro-
moter methylation, which would be protected by methylation 
in MDR tumors. The MDR1 promoter is differentially meth-
ylated in drug sensitive (non-expressing MDR1) and resis-
tant (expressing MDR1) cells, predicting that the promoter is 
hypomethylated in the drug resistant disease and hypermeth-
ylated in the sensitive one [35].  
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The expression level of MGMT, a DNA repair enzyme, 
is proportional to the resistance of tumor cells to che-
motherapic drugs such as cyclophosphamide. It has been 
shown that glioma cells with reduced MGMT expression are 
more sensitive to alkylating agents [58]. Hypermethylation 
of the MGMT promoter also correlate with increased sur-
vival of patients with diffuse large B-cell lymphoma after 
chemotherapy, which included cyclophosphamide [29]. 
FancF is crucial for the activation of a DNA repair complex 
containing BRCA1 and BRCA2 and the inactivation in this 
pathway results to a decreased ability to repair DNA damage 
and an increased susceptibility to develop cancer [59]. Meth-
ylation of the Fancf gene has been observed in ovarian can-
cer [60], acute myeloid leukemia [61], lung and head and 
neck cancers [62], and demethylation of Fancf promoter re-
gion, after treatment with 5-aza-2-deoxycytidine, reduced 
sensitivity towards cisplatin in these cell line models [60]. A 
two-step model for the role of the Fancf gene in tumorigene-
sis and acquired chemoresistance has been proposed [60]. 
According to this model, epigenetic inactivation of Fancf is 
an early event in tumor progression but subsequently chemo-
therapy selects cells in which the Fancf methylation was 
reversed and which, therefore, display higher resistance to 
platinum-based chemotherapy.  
It has been proposed that the opposing processes of re-
gional hypermethylation and global hypomethylation coex-
ists in the same cell and that are two independent processes. 
Both global hypomethylation and regional hypermethylation 
confer a selective advantage upon cancer cells by targeting 
different sets of genes with opposing roles in cellular trans-
formation. Regional hypermethylation targets the silencing 
of genes, which suppress tumorigenesis while global hy-
pomethylation probably targets activation of genes, which 
are required for different stages of the transformation proc-
ess. 
Numerous correlations were obtained between tumor cell 
line chemosensitivity and the expression or mutation of spe-
cific genes. However, considering the effect of factors in 
isolation is insufficient because chemosensitivity involves 
multiple interacting factors that contribute to the overall re-
sponse. There is probably no single gene or small group of 
genes determining the sensitivity or the resistance to a given 
anticancer drug. More likely, the concerted action of several 
genes with suppressive or permissive action eventually de-
termines the activity of the drug towards the tumor cell. Each 
cancer cell represents a different pattern of drug-resistance 
gene expression even within cells clonally derived from the 
same cancer, and may be expected to exhibit a considerable 
amount of heterogeneity with respect to drug resistance [57].  
Epigenetic changes are an important feature of cancer 
cells with acquired drug-resistant phenotype and may be a 
crucial contributing factor to its development. Finally, de-
regulation of similar pathways may explain the existence and 
provide mechanism of cross-resistance of cancer cells to 
different types of chemotherapeutic agents. 
DNA HYPOMETHYLATING AGENTS AND HIS-
TONE DEACETHYLASE INHIBITORS AS THERA-
PEUTIC TOOLS IN CANCER 
The fact that human diseases, including cancer, can have 
an epigenetic etiology has encouraged the development of a 
new therapeutic option that might be termed “epigenetic 
therapy”. Unlike genetic changes, the epigenetic changes in 
cancer are potentially reversible. Reactivation of the silenc-
ing associated with promoter methylation for critical genes 
would be a highly desirable goal for reversing many aspect 
of the cancer cell phenotype. Because methylation causes the 
inactivation of numerous genes that are important in the de-
velopment of most of all tumors types, inhibition of DNA 
methylation and consequent re-activation of these genes is an 
attractive avenue for the development of novel therapeutics. 
1. Epigenetic Therapy – A New Development in Pharma-
cology  
Epigenetic therapy, based on use of drugs able to correct 
epigenetic defects, is a concept that has taken 15 years to 
develop and now represents a new branch of pharmacology.  
The epigenetic therapy developed from the idea of treat-
ing cancer not by killing the cells but by changing their gene 
expression profile. Growing evidence indicates that epige-
netic defects in cancer patients can compromise the response 
to chemotherapy treatment and that it exists a unique profile 
of promoter hypermethylation for each human cancer in 
which some methylated genes are shared and other are tu-
mor-type-specific. On the bases of these finding, it is now 
emerging a new branch of personalized medicine, pharma-
coepigenetics, which studies the patients response to treat-
ment based on individual epigenetic differences, with the 
aim of improving the individual response to therapy [63]. 
The potential reversibility of epigenetic abnormalities has 
encouraged the development of pharmacologic inhibitors of 
DNA methylation and histone deacetylation as anti-cancer 
therapeutics. Two classes of epigenetic drugs are under in-
vestigation to treat cancers: DNA methyltrasferase (DNMT) 
inhibitors target DNA hypermethylation, and histone deace-
tylase (HDAC) inhibitors target histone deacetylation (Table 
1).  
Among the DNMT inhibitors, the nucleoside analogous 
inhibitors 5-azacytidine (5-Aza-CR, Azacitidine, Vidaza) 
and 5-aza-2’-deoxycytidine (5-Aza-CdR, Decitabine, Daco-
gen) are the most extensively studied and they were recently 
approved by the U.S. Food and Drug Administration (FDA) 
as chemotherapeutic agents for myelodysplastic syndromes 
(MDS). These nucleosides are analogous of cytosine and are 
phosphorylated to the deoxynucleotide triphosphate and then 
incorporated into replicating DNA in place of natural base 
cytosine. Once incorporated into the DNA, a complex is 
formed with active sites of DNMTs, thereby covalently trap-
ping these enzymes [64]. This results in the depletion of ac-
tive enzymes and the demethylation of DNA after several 
cell divisions. A difference between 5-azacytidine and 5-aza-
2-deoxycytidine is that the first is partly incorporated into 
RNA, thereby interfering with protein translation, while 5-
aza-2-deoxycytidine is incorporated only into DNA, causing 
more efficient inhibition of DNMTs. The major disadvan-
tages of 5-azacytidine and 5-aza-2-deoxycytidine are their 
instability in neutral aqueous solution and their myelotoxic-
ity resulting in cytopenia. More stable cytidine analogs, such 
as 5,6-dihydro-5-azacytidine and 5-fluoro-2-deoxycytidine 
have been developed. Both these drugs are undergoing Phase  
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Table 1. Classification of Epigenetic Drugs According to Potential Therapeutic Use and Clinical Trials Phase 
 
Inhibitor Alternate Name Use State of Development 
DNA Methyltransferase Inhibitors  
Nucleoside Analogue Inhibitors 
5-azacytidine Azacytidine,  
Vidaza 
MDS 
Solid tumors  
Leukaemia 
FDA approved for clinical use 
Phase II/III 
Phase II/III 
5-aza-2’-deoxycytidine Decitabine, Dacogen MDS 
Leukaemia 
Phase II/III 
Phase II/III 
Zebularine --- Urinary bladder cancer Preclinical 
Arabinosyl-5-azacytidine Fazarabine Leukaemia Phase I/II 
5-6-dihydro-5-azacytidine DHAC Melanoma 
Solid tumors 
Phase I/II 
Phase I/II 
5-fluoro-2’-deoxycytidine FdCyd Cancer Phase I/II 
Non-nucleoside Analogue Inhibitors 
Epigallocatechin-3-Gallate EGCG Photocarcinogenesis 
Cancer of cervix 
Preclinical 
Preclinical 
Procainamide --- Prostate cancer Preclinical 
Procaine --- Breast cancer Preclinical 
Antisense oligonuclotides 
MG98 Dnmt1 Antisense Renal Carcinoma Phase II 
Small Molecule 
RG108 --- --- Preclinical 
HDAC Inhibitors 
Hydroxamates 
Suberic Bishydroxamic Acid SBHA --- --- 
Suberoylanilide Hydroxamic Acid SAHA, vorinostat,  
Zolinza 
Solid Tumors 
Leukaemia, MDS 
Phase I/II 
Phase I/II 
Trichostatin A TSA Breast cancer 
Ovarian cancer 
Preclinical 
Preclinical 
Cyclic hydroxamic-acid-containing 
peptide 1 
CHAP1 --- --- 
LAQ824 NVP-LAQ824 Solid Tumors 
Hematologic Diseases 
Phase I 
Phase I 
Oxamflatin --- --- --- 
PXD101 --- --- Phase I 
Suberoyl-3-aminopyridineamide hy-
droxamic acid 
Pyroxamide Gynecologic cancer Phase I 
Cyclic Tetrapeptides and Analogues 
Apicidin --- Leukaemia Preclinical 
Depsipeptide --- Leukaemia 
Melanoma 
Colon cancer 
Phase I/II 
Preclinical 
Preclinical 
FK228 --- Leukaemia Phase I/II 
FR901218 --- Leukaemia Phase I/II 
Trapoxin A TPX A --- --- 
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Table 1. contd…. 
Inhibitor Alternate Name Use State of Development 
HDAC Inhibitors  
Aliphatic Acids (Short-Chain Fatty Acids) 
Butyrates Phenylbutyrate, Buphenyl MDS, Leukaemia 
Urea cycle disorders 
Phase I 
FDA approved for clinical use 
Valproic acid Depakote, Depakene Bipolar disorder 
Cervical cancer, MDS 
In routine use 
Phase I/II 
Benzamides 
MS-275 --- Solid Tumors, Lymphoma Phase I 
CI-994 N-Acetyl-dinaline Solid Tumors Phase I/II 
MGCD0103 --- Leukemia  
MDS  
Solid tumors 
Phase I/II (combined with Aza-
cytidine) 
 
I and II studies. For 5-Fluoro-2-deoxycytidine has been ob-
served some toxic effect probably due to its metabolites [65, 
66]. Zebularine is a novel cytosine analogous, which is very 
stable, less toxic and can be orally administered. However, it 
has the disadvantage of being much less potent than5-
azacytidine and decitabine and needs to be administered in 
higher doses [67]. Although these properties make zebu-
larine a promising candidate for cancer treatment, the re-
quirement of higher concentrations (up to 1 g/kg body 
weight in the mouse model) in comparison with 5-aza-2-
deoxycytidine has important consequences for the clinical 
potential [68]. The myelotoxicity of nucleoside analogs, as 
sociated with their incorporation into DNA, resulted in the 
search for non-nucleoside DNMT inhibitors. A group of 
non-nucleoside DNMTs inhibitors that are not incorporated 
into DNA because of structural differences from cytosine, 
has been identified. 
Procainamide and procaine inhibit DNMTs by perturbing 
interactions between the protein and its target sites. Both 
these drugs are undergoing preclinical trials because of their 
growth-inhibitory effects in prostatic and breast cancers [69, 
70].  
Another non-nucleoside analogous is epigallocathechin-
3-gallate, a natural product derived from green tea, which 
has shown to inhibit DNMT activity by binding to and 
blocking the active site of human DNMT [71]. RG108 is a 
novel small molecule that blocks the DNMT active site. In-
triguingly, it causes demethylation and reactivation of tumor 
suppressor genes, but does not affect methylation of centro-
meric satellite sequences. These characteristics make RG108 
particularly useful for new drug developmen [72]. Most 
DNMT inhibitors are not specific for a particular DNMT, 
which may result in unfavourable toxicity. Therefore, new 
compounds with specificity for a particular DNMT are being 
developed. Antisense oligonucleotides, such as MG98, that 
are complementary to mRNA for human DNMT1 and able to 
block the translation of DNMT1, are undergoing clinical 
trials [73]. 
As regard HDAC inhibitors, many naturally occurring 
and synthetic histone deacetylase inhibitors have been char-
acterized and some of them displayed anticancer activities in 
preclinical studies. These compounds are structurally hetero-
geneous, and have been classified according to their chemi-
cal nature and mechanism of inhibition such as their affinity 
for the HDACs of classes 1, 2, 4. Among HDAC inhibitors, 
the hydroxamic acids are very potent but reversible HDAC 
inhibitors, that bind more strongly to the HDAC catalytic site 
[74]. Among these compounds is trichostatin A (TSA), 
originally developed as an antifungal agent, which is active 
at nanomolar concentrations [75]. Other hydroxamic acids 
are suberoylanilide hydroxamic acid (SAHA), which has 
been recently approved for therapy of cutaneous T-cell lym-
phomas, pyroxamide, oxamflatin, PXD101, NVP-LAQ824 
and LBH589. The hydroxamate Scriptaid is a novel synthetic 
HDAC inhibitor with a relatively low toxicity. The cyclic 
hydroxamic-acid containing peptide (CHAP) compounds are 
built from TSA and cyclic tetrapeptides and inhibit HDACs 
at nanomolar concentrations [76].  
Other classes of HDAC inhibitors are short chain fatty 
acids (SCFA), benzamides, epoxyketone and non-
epoxyketone containing cyclic tetrapeptides, and hybrid 
molecules. SCFA, although widely used (especially valproic 
acid) and clinically efficacious, have weak HDAC inhibition 
constants.  
The short-chain fatty acids phenylbutyrate and valproic 
acid are relatively old drugs that have been used for non-
oncological uses and recently shown to have activity as 
HDAC inhibitors [74]. These compounds possess an acyl 
group, which contacts the catalytic HDAC zinc ion but can-
not make significant contact with the catalytic pocket due to 
their very short side chains. Therefore, phenylbutyrate and 
valproic acid act as HDAC inhibitors at relatively high con-
centrations. A third class of HDAC inhibitors is the cyclic 
tetrapeptides, including depsipeptide (FK-228, FR901228), 
apicidin and trapoxin. Depsipeptide is a pro-drug that is acti-
vated by reduction upon cellular uptake and inhibits class I 
HDACs, although the exact mechanism of inhibition remains 
unknown [77]. Apicidin is a reversible HDAC inhibitor at 
low nanomolar concentrations, bearing an alkylketone resi-
due that is supposed to chelate the catalytic HDAC zinc ion 
[78]. Trapoxin is closely related to apicidin, and irreversibly 
inactivates HDAC by covalent interaction between its epox-
ide group and the HDAC catalytic site.  
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The benzamides are a structurally diverse fourth class of 
HDAC inhibitors including MS-275 (Benzamidine), CI-994 
and MGCD0103 which act by binding the active zinc in the 
HDAC catalytic site. The synthetic HDAC inhibitor MS-275 
inhibits HDAC at micromolar concentrations. CI-994 (N-
acetyl dinaline) is a relatively weak HDAC inhibitor and the 
mechanism of its action is still unknown. It inhibits histone 
deacetylation, but not by inhibiting HDAC activity. Ben-
zamides, like MS-275, and cyclic peptides, like depsipeptide, 
have been studied in numerous clinical trials and demon-
strated low toxicity and activity in solid and haematological 
neoplasms [76, 79].  
2. Insights on the Clinical Trials with Hypomethylating 
and Deacetylating Agents  
It is clear from in vitro and preclinical studies that the 
clinical application of reversing epigenetic aberrations in 
tumor cells, called epigenetic therapy, is a promising strategy 
for cancer treatment. As previously described, many agents 
have been discovered that inhibit DNA methylation and his-
tone deacetylation. However their therapeutic value will be 
established by ongoing clinical trials. 
Some drugs have been around for decades and have been 
used as chemotherapeutics for cancers and other disease, 
other are of new generation and are under investigation to 
evaluate their possible use in epigenetic therapy. Currently, 
although some DNMT inhibitors received approval to be 
used in Phase I and II clinical trials, no HDAC inhibitors are 
approved for cancer therapy except for suberoylanilide hy-
droxamic acid, or SAHA (Zolinza), which has been submit-
ted as new drug application for treatment of cutaneous T-
Cell lymphoma [80-82]. HDAC are approved for diseases 
other than cancers, including phenylbutyrate (Buphenyl) for 
urea cycle disorders and valproic acid (Depakote) for sei-
zures. Both these short chain fatty acids are under evaluation 
as potential epigenetic cancer drugs [79]. Sodium butyrate 
and sodium phenylbutyrate were the first HDAC inhibitors 
to be tested in cancer patients despite the limitations of low 
potency and lack of specificity of these compounds [83, 84]. 
Phase I clinical and pharmacokinetic studies of sodium 
phenylbutyrate has been evaluated in AML and MDS [85], 
as well as in solid tumor malignancies [86, 87]. Millimolar 
or high micromolar peak plasma concentrations can be 
achieved following intravenous (iv) and oral administration. 
Prolonged iv infusions of sodium phenylbutyrate maintain 
constant circulating concentrations of the drug at potentially 
therapeutic levels but are complicated by somnolence and 
confusion [88]. Sodium phenylbutyrate is well absorbed 
from the gut but very large oral doses of several grams per 
day are needed to achieve biologically active plasma concen-
tration of 0,5 mM. Another short chain fatty acid HDAC 
inhibitor, valproic acid, has been used as an antiepileptic 
drug for many years but only recently it was shown to inhibit 
HDAC at millimolar or high micromolar concentrations [89]. 
Phase I and II clinical trials for evaluating it as an anti-cancer 
agent have been recently reported [90, 91]. Although there is 
a wealth of clinical experience with valproic acid, it suffers 
from the same limitations as the other short-chain fatty acid 
HDAC inhibitors, namely low potency and specificity. There 
are metabolic and other potentially serious dose-related tox-
icities that preclude administration of valproic acid at poten-
tially therapeutic anticancer doses. There are other HDAC 
inhibitors, the bicyclic depsipeptides, in early phase clinical 
development as anticancer drugs for the treatment of solid 
and hematological cancers [92]. FR-901228 is one of these 
compounds to enter clinical trials and is now in phase II de-
velopment [93, 94]. Preclinical studies in rodents showed 
that peak plasma levels in excess of those predicted to be 
therapeutic in vitro could be achieved with single iv or oral 
doses of FR-901228 and could be sustained with iv infusion 
[95]. Preclinical studies predicted significant cardiac and 
catheter-side related toxicity but FR-901228 was well toler-
ated in patients with relatively mild hematological (neutro-
penia, thrombocytopenia) and non-hematological (nau-
sea/vomiting, fatigue, ECG change, hypocalcemia) toxicity 
[96]. Phase I and II studies of FR-901228 confirmed efficacy 
in peripheral and cutaneous T-cell lymphomas and in chronic 
lymphocytic leukemia [94]. Phase I trials with depsipeptide 
have shown encouraging results, especially for patients with 
cutaneous T-cell lymphoma. Phase II studies are ongoing to 
establish their efficacy in a range of solid and hematological 
malignancies [92].  
Among the organic hydroxamic acids, the tricostatin A 
was the first one tested in laboratory but it has limited use 
because its extremely short half-life, and other hydroxamic 
acids have been identified and developed for clinical use 
[97]. Suberoylanilide hydroxamic acid, SAHA, is the most 
advanced in development and is currently under testing in 
both intravenous infusion and oral administration. Encourag-
ing results were obtained in Phase I and II clinical trials for 
patients with both hematologic and solid tumors [98]. A 
phase I study was conducted to evaluate the safety and activ-
ity of oral vorinostat (SAHA) 100-300 mg administered 
twice- or thrice-daily for 14 days followed by 1-week of rest. 
Patients with relapsed or refractory leukemias or myelodys-
plastic syndromes (MDS) and untreated patients who were 
not candidates for chemotherapy were eligible. The maxi-
mum tolerated dose (MTD) was 200 mg twice-daily or 250 
mg thrice-daily. Dose-limiting toxicities were fatigue, nau-
sea, vomiting, and diarrhea [80]. Currently, Phase II study of 
oral vorinostat (SAHA) for refractory cutaneous T-cell lym-
phoma [81] and Phase III clinical trials in patients with ma-
lignant pleural mesothelioma and diffuse large B-cell lym-
phoma are ongoing. While other hydroxamic acids such as 
LAQ824 have entered clinical trials, there is little data pub-
lished about their toxicities or response observed to date. 
Among the favorable aspects of hydroxamic acids are their 
tolerability and oral absorption while one of the main limita-
tions is their short half-life.  
Among the benzamides drugs, a phase I study of MS-275 
has been performed in patients with advanced solid tumors 
or lymphoma [99]. In this study a cohort of patients treated 
with MS-275 daily showed severe toxicity, including ele-
vated liver enzymes, hypophosphatemia, hypoalbuminemia 
and pleural effusion. Pharmacokinetic analysis showed that 
MS-275 had a much longer half-life than expected. The trial 
was revised to evaluate the true half-life and the MS-275 was 
administered either once every 7 or 14 days. The observed 
toxicities included fatigue, nausea, vomiting, hypoalbu-
minemia, anxiety, dyspepsia, anemia, fever and dysgeusia. 
Currently, Phase II clinical trials is undergoing in patients 
with advanced and refractory solid tumors and lymphoma 
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[100]. Phase I clinical trial of chronic administration of ace-
tyldinaline CI-994 was recently published [101], where 
orally daily administration for 8 weeks was done in patients 
with non-small lung cancer. The observed maximum toler-
ated dose was 8mg/m2/d and dose limiting toxicities were 
neutropenia and thrombocytopenia with other effect reported 
as leukopenia, nausea, vomiting, diarrhea, fatigue and ano-
rexia. In this study it was observed an adaptation phenome-
non of the platelet count, which rebounded after the first 
month of therapy. Phase II studies have been also conducted 
in patients with advanced non-small cell lung cancer, metas-
tatic renal cell carcinoma and advanced pancreatic cancer 
[102, 103]. However, Phase II of its activity as monotherapy 
have proved disappointing and further phase II trials of CI-
994 in combination with chemotherapeutic agents as capecit-
abine, gemcitibine, or carboplatin with paclitaxel are under-
way [104].  
The favorable aspects of the benzamides include their 
tolerability and oral absorption. While the unexpectedly long 
half-life of these compounds may be a favorable attribute, 
the best schedule has yet to be determined.  
Many questions still remain unanswered regarding the 
optimal evaluation and utilization of HDAC inhibitors for 
cancer prevention and treatment. It is still unclear whether 
the clinical effects of HDAC inhibitors are the results of al-
terations of histone acetylation patterns or of increased non-
histone proteins acetylation, which determines changes in 
growth regulatory pathways. Due to existence of many dif-
ferent HDACs it is crucial to understand the specificity of 
the existing HDAC inhibitors as well as to develop selective 
inhibitors that target individual enzymes.  
Many agents have been discovered that inhibit DNA 
methylation and with respect to HDAC inhibitors the value 
of these compounds as efficient anti-cancer drugs is well 
established. 5-Azacytidine and 5-Aza-2’-deoxicitidine repre-
sent the most prominent DNMT inhibitors used in clinical 
practice [105] and that they received the FDA approval.  
The nucleoside inhibitors, 5-azacytidine (Vidaza) and 5-
Aza-2’-deoxicitidine (decitabine), have been tested in phase 
I and II trials against many forms of cancer. The dose-
limiting toxicity for both is myelosuppression, and the most 
commonly reported non-hematologic adverse effect was 
nausea and vomiting. In lung cancer patients, toxicity was 
both dose and schedule dependent, with decitabine being less 
myelosuppressive when the same dose was administered 
over a shorter treatment period than over a longer period 
[106]. At cytotoxic doses, decitabine was active against leu-
kemia and myelodysplastic syndromes, but only limited ac-
tivity with these schedules and doses was observed against 
solid tumors [107, 108]. More recently Phase II and III clini-
cal trials have been conducted for the treatment of myelo-
dysplastic syndrome (MDS) and chronic myelogenous leu-
kemia by using low-dose 5-azacytidine or decitabine and 
significantly higher response rates were reported in the pa-
tient group treated with demethylating agents as compared 
with the group receiving supportive care only. Also the qual-
ity of life was significantly improved in the group that re-
ceived aza-nucleoside treatments [109, 110]. These results 
led to recent FDA approval of 5-azacytidine (Vidaza) for 
treatment of all MDS subtype and to the fast-track status of 
Decitabine (Dacogen) for MDS [111]. Because decitabine 
also showed promising response rates for other leukemia 
[112, 113], it might be effective for other tumor types. How-
ever, the activity of decitabine in solid tumor remain unclear, 
although prolonged disease stabilization has been reported in 
patients with lung cancer, prostate cancer and other thoracic 
malignancies [106, 114, 115]. Although these demethylating 
agents have shown clinical benefit, there are several pitfalls 
regarding their clinical application. Their specificity on 
DNMT inhibition, reversal methylation and gene reactivation 
is not entirely clear. Many of nucleoside demethylating drugs 
are not specific for particular DNMT or gene and some of 
them showed high toxicity mediated primarily by covalent 
trapping of DNA methyltrasferase rather than DNA methyla-
tion [116]. Toxicity, a central problem in interpretating clini-
cal data, might be reversed by optimizing treatment sched-
ules e.g. giving lower doses over longer time periods [110] 
as well as by developing non-nucleoside inhibitors which 
may be less toxic because they are not incorporated into 
DNA. Non-nucleoside inhibitors such as EGCG, RG108 and 
procaine are now under evaluation in preclinical and clinical 
studies [117-119]. Also new compounds with specificity for 
particular DNMT might reduce nonspecific effects and hold 
promise for a more targeted approach towards methylation. 
Of these compounds, MG98 is currently being tested in 
Phase II clinical trial [120].  
Targeting epigenetic gene regulation may require a com-
bination of chromatin modifying agents. Recently, on the 
base of a multitude of experimental results, many epigenetic 
investigators believe some of these drugs might work better 
together than individually. Some HDAC inhibitors have been 
definitively shown to be synergistic with DNMT inhibitors 
in reacting gene expression in vitro and therefore there is the 
possibility that they will be clinically synergistic also, but the 
verdict is still out on that. Preclinical and Phase I/II clinical 
studies of DNA methyltransferase and histone deacetylase 
inhibitors have yielded encouraging results, especially 
against hematologic malignancies [121]. It has been reported 
clinical trial in which demethylating agent combined with 
HDAC inhibitor was administered to patients with hemato-
logical and solid tumors, achieving complete and partial re-
missions [122, 123]. Recently, Phase I study of decitabine in 
combination with valproic acid has been evaluated [124] as 
well as Phase I/II clinical trials of HDAC inhibitor 
MGCD0103 combined with azacytidine is actually evaluat-
ing in patients with either MDS or acute myeloid leukemia 
(AML) [125]. 
In conclusion targeting of cancer through demethylation 
and histone acetylation proves to be an exiting area of cancer 
therapy. At this time development of second generation in-
hibitors of DNA methyltrasferase and HDAC is in progress 
and their efficacy as anti-tumoral drugs will ultimately re-
quire evaluation in monotherapy and in combination. The 
manipulation of gene expression through epigenetic modifi-
cations heralds a new era of gene-targeted therapy and holds 
promise as both therapeutic and preventive strategy.  
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